今日，港股新上市公司映恩生物（09606.HK）股价表现强劲，盘中大涨114.59%，引发市场广泛关注。该公司是一家专注于抗体偶联药物（ADC）研发的创新生物制药企业，其上市首日的亮眼表现反映了投资者对其发展前景的看好。
映恩生物此次IPO定价为每股94.6港元，发行1733.23万股股份。公开发售部分获得约115倍超额认购，显示出投资者的热烈追捧。在昨日的暗盘交易中，映恩生物已上涨87.1%，为今日的强劲开盘奠定了基础。今日开盘价为181港元，较发行价大幅上涨91.33%。
映恩生物成立于2020年，已迅速成为ADC领域的全球领先企业。公司拥有两款自主研发的核心产品，分别针对HER2癌症和B7-H3癌症。此外，公司还有五项处于临床阶段的资产已获得美国FDA和中国国家药品监督管理局的IND批准。映恩生物已与多家全球领先的生物制药公司建立合作关系，包括BioNTech、百济神州等，合作交易总价值超过60亿美元。投资者看好公司在ADC创新药物研发领域的领先地位和未来增长潜力，推动了股价的大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.